Compare ADMA Biologics Inc (ADMA) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs WD 40 Company — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while WD 40 Company trades at $233.59 (market cap $3.15B). The key difference: WD 40 Company is the larger of the two by market cap, and WD 40 Company pays a 1.74% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | WDFC | |
|---|---|---|
Market Cap | $2.18B | $3.15B |
Sector | Health | Technology |
52-Week High | $20.38 | $264.91 |
52-Week Low | $7.60 | $187.52 |
Enterprise Value | $2.25B | $3.20B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
WDFC trades at $234.93, up 1.61% today, with a bullish technical outlook supported by moving averages but neutral oscillators. Recent Q2 2026 earnings beat expectations at $2.33 EPS, though Q4 2025 missed. The company maintains strong profitability with a 55.82% gross margin and 13.22% net margin, while valuation ratios like P/E of 35.64 suggest a premium. A quarterly dividend of $1.02 was declared, payable July 31, 2026.
Outlook is mixed: solid brand strength and cash flow support growth, but high input costs pressure margins. Risks include competitive threats and valuation concerns. Analyst consensus is cautious with 71.42% hold ratings. Upside hinges on margin stability and execution of clear growth strategies amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
